1153. Safety and Potential Efficacy of Exosomes Overexpressing CD24 (EXO-CD24) for the Prevention of Clinical Deterioration in Patients with Moderate or Severe COVID-19: A Phase II, Randomized, Single-blinded Study.

BACKGROUND: EXO-CD24 is a novel inhaled drug of exosomes displaying CD24, a protein with anti-inflammatory properties. We evaluated the safety and potential efficacy of EXO-CD24, in a phase II, randomized, single-blinded clinical trial of EXO-CD24 in hospitalized patients with moderate or severe COV...

Descripción completa

Detalles Bibliográficos
Autores principales: Grigoropoulos, Ioannis, Tsioulos, Georgios, Kastrissianakis, Artemis, Shapira, Shiran, Arber, Nadir, Poulakou, Garyfallia, Syrigos, Konstantinos, Rapti, Vasiliki, Xynogalas, Ioannis, Leontis, Konstantinos, Ntousopoulos, Vasileios, Sakka, Vissaria, Gaga, Mina, Sardelis, Zafeiris, Fotiadis, Andreas, Vlassi, Lamprini, Kontogianni, Chrysoula, Levounets, Anastasia, Tsakona, Maria, Savva, Athina, Kavatha, Dimitra, Boumpas, Dimitrios, Antoniadou, Anastasia, Tsiodras, Sotirios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752112/
http://dx.doi.org/10.1093/ofid/ofac492.991

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752112/
http://dx.doi.org/10.1093/ofid/ofac492.991

Ejemplares similares